Showing results (31-40 of 42) with videos related to
Sort By:
Pageof 5
JGH Open : an Open Access Journal of Gastroenterology and Hepatology|March 18, 2021
Ustekinumab in Crohn's disease: Real-world outcomes from the Sicilian network for inflammatory bowel diseasesAnna Viola, Marco Muscianisi, Fabio S Macaluso, et al.Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|July 16, 2018
A real life comparison of the effectiveness of adalimumab and golimumab in moderate-to-severe ulcerative colitis, supported by propensity score analysisSara Renna, Filippo Mocciaro, Marco Ventimiglia, et al.Journal of Gastroenterology and Hepatology|May 20, 2020
A propensity score weighted comparison of vedolizumab and adalimumab in Crohn's diseaseFabio Salvatore Macaluso, Marco Ventimiglia, Walter Fries, et al.Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|August 27, 2025
Comparative effectiveness and safety of tofacitinib and filgotinib in patients with ulcerative colitis: A propensity score-weighted cohort studyFabio Salvatore Macaluso, Walter Fries, Anna Viola, et al.Expert Opinion on Biological Therapy|September 28, 2020
Effectiveness of Ustekinumab on Crohn's Disease Associated Spondyloarthropathy: Real-World Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD)Fabio Salvatore Macaluso, Walter Fries, Anna Viola, et al.Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|July 1, 2020
A propensity score weighted comparison of Vedolizumab, Adalimumab, and Golimumab in patients with ulcerative colitisFabio Salvatore Macaluso, Marco Ventimiglia, Walter Fries, et al.Inflammatory Bowel Diseases|February 22, 2020
The SPOSIB SB2 Sicilian Cohort: Safety and Effectiveness of Infliximab Biosimilar SB2 in Inflammatory Bowel Diseases, Including Multiple SwitchesFabio Salvatore Macaluso, Walter Fries, Anna Viola, et al.Drugs & Aging|February 5, 2020
Persistence on Anti-Tumour Necrosis Factor Therapy in Older Patients with Inflammatory Bowel Disease Compared with Younger Patients: Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD)Serena Porcari, Anna Viola, Ambrogio Orlando, et al.Journal of Gastroenterology and Hepatology|May 6, 2023
Ustekinumab is a promising option for the treatment of postoperative recurrence of Crohn's diseaseFabio Salvatore Macaluso, Mauro Grova, Filippo Mocciaro, et al.Journal of Gastroenterology and Hepatology|June 21, 2021
SPOSAB ABP 501: A Sicilian Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Adalimumab Biosimilar ABP 501Fabio Salvatore Macaluso, Maria Cappello, Anita Busacca, et al.Pageof 5